about
Mesenchymal Stromal Cells: Updates and Therapeutic Outlook in Rheumatic DiseasesAnti-neutrophil cytoplasmic antibodies in rheumatoid arthritis: two case reports and review of literature.X-Linked miRNAs Associated with Gender Differences in Rheumatoid Arthritis.Essential competencies in prescribing: A first european cross-sectional study among 895 final-year medical students.TMEM187-IRAK1 Polymorphisms Associated with Rheumatoid Arthritis Susceptibility in Tunisian and French Female Populations: Influence of Geographic OriginmiR-125b controls monocyte adaptation to inflammation through mitochondrial metabolism and dynamics.Circulating miRNA-125b is a potential biomarker predicting response to rituximab in rheumatoid arthritisMicroRNA in 2012: Biotherapeutic potential of microRNAs in rheumatic diseases.A severe Whipple disease with an immune reconstitution inflammatory syndrome: an additional case of thalidomide efficiency.Non-TNF-Targeted Biologic vs a Second Anti-TNF Drug to Treat Rheumatoid Arthritis in Patients With Insufficient Response to a First Anti-TNF Drug: A Randomized Clinical Trial.Adipose derived stem cells for regenerative therapy in osteoarticular diseases.Characteristics of the musculoskeletal symptoms observed among survivors of Ebola virus disease in the Postebogui cohort in Guinea.Perspectives of ofatumumab as CD20 targeted therapy in rheumatoid arthritis and other autoimmune diseases.[Acute Q fever, antiphopholipid antibodies and renal artery thrombosis: case report and literature review].Nicotinamide phosphoribosyltransferase/visfatin expression by inflammatory monocytes mediates arthritis pathogenesis.Targeted delivery to inflammatory monocytes for efficient RNAi-mediated immuno-intervention in auto-immune arthritis.Genetic markers in clinical subtypes of juvenile idiopathic arthritis.BIK is a novel pro-apoptotic target gene for miR-125b in human monocytes.Poor efficacy of TNF inhibitors in non-radiographic axial spondyloarthritis in the absence of objective signs: A bicentric retrospective study.Tocilizumab and mesenteric arterial thrombosis: drug-drug interaction with anticoagulants metabolized by CYP 450 and/or by P-glycoprotein.Cholangiocarcinoma occurring in a patient with type 1 Gaucher disease treated with velaglucerase alfa enzyme replacement therapy: First case report.Effects of switching from imiglucerase to velaglucerase alfa without dose reduction nor wash out in type 1 Gaucher disease.NAMPT/Visfatin expression by inflammatory monocytes mediates arthritis pathogenesis by promoting IL-17–producing T cellsInjection of Adipose-Derived Stromal Cells in the Knee of Patients with Severe Osteoarthritis has a Systemic Effect and Promotes an Anti-Inflammatory Phenotype of Circulating Immune CellsDelivery of miR-146a to Ly6C Monocytes Inhibits Pathogenic Bone Erosion in Inflammatory Arthritis[Ma2 antibody and multiple mononeuropathies]GQ1b ganglioside antibody-related disorders: a case with a complex phenotypeIsolation of functional autologous collagen-II specific IL-10 producing Tr1 cell clones from rheumatoid arthritis blood[Postoperative discitis due to Propionibacterium acnes]Mesenteric and splenic cat-scratch disease during etanercept therapyUnusual seminoma revealed by bone metastasisPredictors of response and remission in a large cohort of rheumatoid arthritis patients treated with tocilizumab in clinical practiceTNFRII polymorphism is associated with response to TNF blockers in rheumatoid arthritis patients seronegative for ACPAAcute inflammatory myalgia: think of myositis ossificans circumscriptaCardiac Complications Attributed to Chloroquine and Hydroxychloroquine: A Systematic Review of the LiteratureImmunoglobulin Abnormalities in Gaucher Disease: an Analysis of 278 Patients Included in the French Gaucher Disease RegistryTGFβi is involved in the chondrogenic differentiation of mesenchymal stem cells and is dysregulated in osteoarthritisSuccessful long-term remission through tapering tocilizumab infusions: a single-center prospective studyTreatment of refractory adult onset Still's disease with combination anakinra and baricitinib therapy[Mesenchymal stem cells and regenerative medicine: future perspectives in osteoarthritis]
P50
Q35750457-20F834CE-82DB-4ADF-A0A4-6D58192508C1Q36555759-5D36AED4-E216-4E61-BECA-6E3E1CAC1583Q37465525-BE45FA33-5D41-44B5-8C15-2A5CF98388C1Q37602796-138A5A55-D6F0-4CB5-82D5-5F302BA33AF0Q37657331-9CBE5090-FD3A-43D6-A0AE-733FC98809DDQ37679172-4B8F7E98-9DC2-4AF5-B074-F3F9EA88235CQ37693747-FEE5B53A-0A13-4269-9C6E-272A1B81719DQ38074277-E69EEB68-C61E-4D8E-A817-5851D0489212Q38167411-BC5CD81B-F385-47E9-981B-859E2EE410A8Q38387307-9FB6FE52-3C95-41D0-92F4-39984EC75606Q38811688-38AFB59A-D181-429E-A378-35D43AFDBE3AQ38858551-46D36631-DF16-472A-A17B-59A1FC35A611Q38916526-E45309E2-6565-402D-AD6A-39932E1D536CQ40404307-C48C04B1-E0B4-4E31-B6BD-40D6468FA126Q45950376-05A3834A-D7C9-4D06-AF7D-EC7344B1BEBDQ46090062-62D87942-089E-4381-8A17-6754B72DDE17Q46090317-DEEE531E-5693-4DE8-B059-2462F96A4832Q47158295-1A2168AB-5056-4CC9-A7B4-C0BC9FE4D63DQ47791572-940E48FE-8160-4994-A804-CBE3843AF51EQ48143463-6E519820-B432-4654-8A3F-190C00BDB517Q53257964-244A8EF1-783C-4B87-B634-2BE8C1DD7C94Q53743661-92A9B50A-51FD-44E9-9975-9DF05E5876BEQ59271528-1D4753FF-341D-4FB6-8DE8-942A29AB5FAFQ59806505-08F42DD8-5497-4879-99C3-2B38000E41CEQ61651899-D49550E9-93A6-49BD-9575-A25BD99ABA43Q81483444-20BED2F9-1D35-49C7-9B91-A7A93891822AQ82724988-9A5F5EEC-D173-4A65-B0C5-88C7B5523C37Q83619000-80EDEA97-FAD4-4452-9CFD-8E7FB40E57C6Q84281556-9B28B452-63BD-4CDA-A05B-2D79DEF1DF2FQ84426386-B9CC29D0-1C1D-4E0A-A75B-9B2A48A6B3BBQ84493822-645B39E3-E816-45A2-BE25-0536C695D318Q85964016-6770A7CA-8501-4352-A848-6D722030B2CFQ87162110-F7DF565E-3B93-4DE9-8480-79223453CE8AQ87345708-4A862D64-1007-4C7B-B7B7-06BD7F855C5CQ88956497-859D4571-4BD8-44B4-A5C0-7BD91972A5F8Q89761817-C9639148-7AA4-41B0-BE9A-20340D9992CFQ90015926-CBEDAB15-D2A2-4DB4-8A1A-5763606C7EC4Q90250659-5F5F0D96-F125-438D-96D3-059C805E50F7Q90780537-768D9F8B-40D7-4C20-8B56-44FF98FFAE32Q90956646-379EB5CD-4DE8-4FA3-9D86-0067A4E1742C
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Yves-Marie Pers
@ast
Yves-Marie Pers
@en
Yves-Marie Pers
@es
Yves-Marie Pers
@nl
type
label
Yves-Marie Pers
@ast
Yves-Marie Pers
@en
Yves-Marie Pers
@es
Yves-Marie Pers
@nl
prefLabel
Yves-Marie Pers
@ast
Yves-Marie Pers
@en
Yves-Marie Pers
@es
Yves-Marie Pers
@nl
P106
P31
P496
0000-0001-5927-3773